

DILIGENCE COMMITTEE FACE-TO-FACE MEETING

Agenda

- Introductions
- Purpose of the meeting
- Company Presentation/questions/answers
- Wrap up & action item list




Present today

- Angel Roundtable, Johnson City, TN (Tony Lettich, Richard Sheehan)
- Northwest Georgia Regional Angel Network, Rome, GA (Tony Samples)
- Startup angel group, Memphis, TN (Austin Baker)
- Angel Capital Association Life Sciences Syndication Group (Faz Bashi)
- Patrick Robbins, ASC domain expert
- Ariel Savannah Angel Partners, Savannah, GA (Ray Wenig)
- Wilmington Investor Network, Wilmington, NC (Michael Cain)
- Angel Syndicates Central partners
 - Dick Reeves
 - Chip Manning
 - Adam Pearson
- Entac Medical
 - Buddy Lyons, CEO
 - Richard Jones, Chairman
 - Andrew Forsdick, CFO



The Syndication Deal Cycle



Diligence Philosophy

It is far more important to successfully invest in a company that goes on to be a winner

Than it is to avoid investing in a few losers



- 1. Management team & board
- Product, Markets, & Business model
- Sales & Marketing
- 4. Competition & Competitive advantage
- Legal & regulatory
- 6. Intellectual property & Technology
- 7. Financials
- Exit strategy
- Other investors
- 10. Valuation & terms, Potential for Investors
- 11. Risks



- Management team & board
- 2. Product, Markets, & Business model
- Sales & Marketing
- 4. Competition & Competitive advantage
- Legal & regulatory
- 6. Intellectual property & Technology
- 7. Financials
- Exit strategy
- Other investors
- 10. Valuation & terms, Potential for Investors
- 11. Risks



- Management team & board
- Product, Markets, & Business model
- 3. Sales & Marketing
- 4. Competition & Competitive advantage
- Legal & regulatory
- 6. Intellectual property & Technology
- 7. Financials
- Exit strategy
- Other investors
- 10. Valuation & terms, Potential for Investors
- 11. Risks



- Management team & board
- Product, Markets, & Business model
- Sales & Marketing
- 4. Competition & Competitive advantage
- Legal & regulatory
- 6. Intellectual property & Technology
- 7. Financials
- Exit strategy
- Other investors
- 10. Valuation & terms, Potential for Investors
- 11. Risks



- Management team & board
- 2. Product, Markets, & Business model
- Sales & Marketing
- 4. Competition & Competitive advantage
- 5. Legal & regulatory
- 6. Intellectual property & Technology
- 7. Financials
- Exit strategy
- Other investors
- 10. Valuation & terms, Potential for Investors
- 11. Risks



- Management team & board
- Product, Markets, & Business model
- Sales & Marketing
- 4. Competition & Competitive advantage
- Legal & regulatory
- 6. Intellectual property & Technology
- 7. Financials
- Exit strategy
- Other investors
- 10. Valuation & terms, Potential for Investors
- 11. Risks



- Management team & board
- 2. Product, Markets, & Business model
- Sales & Marketing
- 4. Competition & Competitive advantage
- Legal & regulatory
- 6. Intellectual property & Technology
- 7. Financials
- Exit strategy
- Other investors
- 10. Valuation & terms, Potential for Investors
- 11. Risks



- Management team & board
- Product, Markets, & Business model
- Sales & Marketing
- 4. Competition & Competitive advantage
- Legal & regulatory
- 6. Intellectual property & Technology
- Financials
- 8. Exit strategy
- Other investors
- 10. Valuation & terms, Potential for Investors
- 11. Risks



- Management team & board
- Product, Markets, & Business model
- Sales & Marketing
- 4. Competition & Competitive advantage
- Legal & regulatory
- 6. Intellectual property & Technology
- Financials
- Exit strategy
- 9. Other investors
- 10. Valuation & terms, Potential for Investors
- 11. Risks



- Management team & board
- Product, Markets, & Business model
- Sales & Marketing
- 4. Competition & Competitive advantage
- Legal & regulatory
- 6. Intellectual property & Technology
- 7. Financials
- 8. Exit strategy
- Other investors
- 10. Valuation & terms, Potential for Investors
- 11. Risks



- Management team & board
- 2. Product, Markets, & Business model
- Sales & Marketing
- 4. Competition & Competitive advantage
- Legal & regulatory
- 6. Intellectual property & Technology
- Financials
- Exit strategy
- Other investors
- 10. Valuation & terms, Potential for Investors
- 11. Risks



Diligence Schedule

- \square Diligence meeting #4 Wednesday, 7/30 11 AM cdt
- \blacksquare Final meeting #5 Monday, 8/4 11 AM cdt
- \square Road show available beginning Wednesday, 8/13



Recording

A recording of this session will be posted on Vimeo within the hour, and a link will be sent to all for you to use in bringing in other participants from your group.





DILIGENCE COMMITTEE

The Syndication Deal Cycle

